Multiple Sclerosis
Conference Coverage
To prevent MS, should we target EBV?
Can a vaccine against EBV reduce MS incidence on a population level? Two experts debate.
Conference Coverage
Differential diagnosis in MS: What to watch for
‘Red flags’ suggest something other than MS.
Conference Coverage
CBT alone and with meds may decrease MS fatigue
“Clinicians should consider clinical characteristics and overall treatment goals when selecting fatigue interventions, to offer a more...
Expert Perspective
Anti-CD20 Monoclonal Antibodies for Treating Multiple Sclerosis
Literature Review
Biosimilar equal to natalizumab for relapsing remitting MS
Biosim-NTZ is the first biosimilar monoclonal antibody therapy to be developed for MS.
Opinion
Despite ongoing challenges, experts are optimistic about the future of MS therapy
To celebrate our 30th year in print, Neurology Reviews invited experts to look back on the trajectories of various neurology subspecialties. In...
Literature Review
Stem cell transplant superior to DMTs for secondary progressive MS
More than 60% of patients with SPMS who received AHSCT were free from disability progression at 5 years.
Literature Review
Four-gene signature linked to increased PML risk
Investigators have identified four immune-associated genes that put immunocompromised patients at risk for progressive multifocal...
Expert Perspective
MS and Emotional Stress: Is There a Relation?
Literature Review
High drug costs exclude most neurology patients from cutting-edge treatment
“Our study of people with neurologic conditions found that fewer than 20% were being treated with new medications.”